Recommendations for Cervical Cancer Prevention in Asia Pacific

Vaccine

Volumn 26, Issue SUPPL. 12, 2008, Pages

  Garland, Suzanne M ^a   Cuzick, Jack ^b   Domingo, Efren J ^c   Goldie, Sue J ^d   Kim, Young Tak ^e   Konno, Ryo ^f   Parkin, D Maxwell ^g   Qiao, You Lin ^h   Sankaranarayanan, Rengaswamy ⁱ   Stern, Peter L ^j   Tay, Sun Kuie ^k   Bosch, F Xavier ^l  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e University of Ulsan   (South Korea)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h CANCER HOSPITAL   (China)

ⁱ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k SINGAPORE GENERAL HOSPITAL   (Singapore)

^l CATALAN INSTITUTE OF ONCOLOGY   (Spain)

more..

Author keywords

Asia Pacific; Australasia; Cervical cancer; Cytology; HPV; HPV Vaccination; Oceania; Screening

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; ASIA; AUSTRALIA; CANCER CONTROL; CANCER PREVENTION; CANCER SCREENING; EVIDENCE BASED MEDICINE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; PACIFIC ISLANDS; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; ASIA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; IMMUNIZATION PROGRAMS; MALE; MASS SCREENING; MIDDLE AGED; PACIFIC ISLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 51049086126     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.020     Document Type: Article

References (35)

1. Konno R., Shin H.-R., Kim Y.-T., Song Y.S., Sasagawa T., Inoue M., et al. Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea. Vaccine 26 Suppl 12 (2008) M30-M42
2. Sankaranarayanan R., Bhatla N., Gravitt P., Basu P., Esmy P.O., Ashrafunnessa K.S., et al. Human Papillomavirus Infection and Cervical Cancer Prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 26 Suppl 12 (2008) M43-M52
3. Shi J.-F., Qiao Y.-L., Smith J.S., Dondog B., Bao Y.-P., Dai M., et al. Epidemiology and Prevention of Human Papillomavirus and Cervical Cancer in China and Mongolia. Vaccine 26 Suppl 12 (2008) M53-M59
4. Tay S.K., Ngan H., Chu T.-Y., Cheung N.Y.A., and Tay E.H. The Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong. Singapore and Taiwan. Vaccine 26 Suppl 12 (2008) M60-M70
5. Domingo E.J., Noviani R., Noor M.R., Ngelangel C., Limpaphayom K.K., Thuan T.V., et al. Epidemiology and Prevention of Cervical Cancer in Indonesia, Malaysia, Philippines, Thailand and Vietnam. Vaccine 26 Suppl 12 (2008) M71-M79
6. Garland S.M., Brotherton J.M.L., Skinner S.R., Pitts M., Saville M., Mola G., et al. Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention. Vaccine 26 Suppl 12 (2008) M80-M88
7. United Nations (UN), Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2004 Revision. CD-ROM Edition - Extended Dataset. United Nations publications, Sales No. E.05.XIII.12. 2005.
8. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, version 2.0 Lyon: IARC Press; 2004.
9. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7 7 (2007) 453-459
10. Inoue M., Sakaguchi J., Sasagawa T., and Tango M. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16 3 (2006) 1007-1013
11. Shin H., Lee D., Herrero R., Smith J., Vaccarella S., Hong S., et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 103 3 (2003) 413-421
12. Joo W., Kim S., Kim D., Suh D., Kim J., Kim Y., et al. Prevalence of human papillomavirus infection in Korean women: Risks of abnormal Pap smear and cervical neoplasia. Korean J Gynecol Oncol Colpos 15 4 (2004) 309-316
13. Oh J.K., Ju Y.H., Franceschi S., Quint W., and Shin H.R. Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis 8 (2008) 13
14. Franceschi S., Herrero R., Clifford G.M., Snijders P.J., Arslan A., Anh P.T., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119 11 (2006) 2677-2684
15. Huang Y.K., You S.L., Yuan C.C., Ke Y.M., Cao J.M., Liao C.Y., et al. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer 98 5 (2008) 863-869
16. th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 2007: LA-09.
17. Parkin D.M., Louie K., and Clifford G. Burden and Trends of Type-specific Human Papillomavirus Infections and Related Diseases in the Asia-Pacific region. Vaccine 26 Suppl. 12 (2008) M1-M16
18. Fotinatos N., Warmington A., Walker T., and Pilbeam M. Estimates for cervical abnormalities in Vanuatu. Aust N Z J Public Health 31 6 (2007) 571-575
19. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
20. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (2008) 1915-1927
21. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
22. Skinner S.R., Imberger A., Nolan T., Lester R., Glover S., and Bowes G. Randomised controlled trial of an educational strategy to increase school-based adolescent hepatitis B vaccination. Aust N Z J Public Health 24 3 (2000) 298-304
23. Rosenthal D., Dyson S., Pitts M., and Garland S. Challenges to accepting a human papilloma virus (HPV) vaccine: a qualitative study of Australian women. Women Health 45 2 (2007) 59-73
24. Pitts M.K., Dyson S.J., Rosenthal D.A., and Garland S.M. Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia. Sex Health 4 3 (2007) 177-180
25. Shapiro C. WHO and Adolescent Immunization. Viral Hepatitis Prevention Board Meeting. March 2007. Ljubljana, Slovenia.
26. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
27. th Annual International Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, September 2007.
28. Schiffman M., and Castle P.E. The promise of global cervical-cancer prevention. N Engl J Med 353 20 (2005) 2101-2104
29. Skinner S.R., Garland S.M., Stanley M.A., Pitts M., and Quinn M.A. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?. Med J Aust 188 4 (2008) 238-242
30. Andrus J.K., Sherris J., Fitzsimmons J., Kane M., and Aguado T. Introduction of human papillomavirus vaccines into developing countries: international strategies for funding and procurement. Vaccine 26 Suppl. 10 (2008) K87-K92
31. Goldie S., Diaz M., Kim S., Levin C., van Minh H., and Kim J. Mathematical models of cervical cancer prevention in the Asia Pacific Region. Vaccine 26 Suppl. 12 (2008) M17-M29
32. World Health Organization (WHO). Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization. 2001.
33. World Health Organization (WHO) Statistical Information System: CHOICE (CHOosing Interventions that are Cost Effective). Available at: http://www.who.int/choice/en/ (last accessed: April 2008).
34. Goldie S.J., Diaz M., Constenla D., Alvis N., Andrus J.K., and Kim S.Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 26 Suppl. 11 (2008) L59-L72
35. Kim J., Brisson M., Edumunds J., and Goldie S. Modelling cervical cancer prevention in developed countries. Vaccine 26 Suppl. 10 (2008) K76-K86